William Greenfield
Concepts (87)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Papillomavirus Infections | 6 | 2019 | 155 | 1.120 |
Why?
| Human papillomavirus 16 | 6 | 2019 | 44 | 0.850 |
Why?
| Uterine Cervical Neoplasms | 4 | 2021 | 276 | 0.480 |
Why?
| Oncogene Proteins, Viral | 2 | 2011 | 52 | 0.440 |
Why?
| Cervix Uteri | 3 | 2021 | 49 | 0.440 |
Why?
| T-Lymphocytes | 2 | 2013 | 339 | 0.420 |
Why?
| Repressor Proteins | 2 | 2011 | 153 | 0.410 |
Why?
| Papillomavirus Vaccines | 3 | 2019 | 61 | 0.380 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2012 | 128 | 0.350 |
Why?
| Uterine Cervical Dysplasia | 2 | 2015 | 49 | 0.220 |
Why?
| Papillomaviridae | 2 | 2015 | 102 | 0.210 |
Why?
| Quarantine | 1 | 2021 | 12 | 0.190 |
Why?
| Viral Load | 2 | 2019 | 77 | 0.170 |
Why?
| DNA | 1 | 2021 | 541 | 0.150 |
Why?
| Adult | 9 | 2021 | 13324 | 0.130 |
Why?
| Labor, Induced | 1 | 2015 | 25 | 0.130 |
Why?
| Cross Protection | 1 | 2015 | 5 | 0.130 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2016 | 86 | 0.130 |
Why?
| Epitopes | 1 | 2015 | 61 | 0.120 |
Why?
| Colposcopy | 1 | 2015 | 18 | 0.120 |
Why?
| Delivery, Obstetric | 1 | 2015 | 122 | 0.120 |
Why?
| Female | 11 | 2024 | 26635 | 0.120 |
Why?
| Intensive Care Units, Neonatal | 1 | 2015 | 115 | 0.120 |
Why?
| Cesarean Section | 1 | 2015 | 187 | 0.120 |
Why?
| Papillomavirus E7 Proteins | 2 | 2011 | 31 | 0.110 |
Why?
| Vaginal Smears | 2 | 2011 | 27 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 253 | 0.110 |
Why?
| DNA, Viral | 2 | 2011 | 134 | 0.110 |
Why?
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 2 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 244 | 0.100 |
Why?
| Humans | 14 | 2024 | 50208 | 0.100 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2012 | 24 | 0.100 |
Why?
| Interferon-gamma | 1 | 2012 | 176 | 0.100 |
Why?
| Young Adult | 4 | 2019 | 3981 | 0.100 |
Why?
| Arkansas | 2 | 2015 | 1985 | 0.090 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2011 | 164 | 0.090 |
Why?
| Middle Aged | 6 | 2019 | 12206 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 454 | 0.080 |
Why?
| Telemedicine | 1 | 2015 | 449 | 0.080 |
Why?
| Vaccinia virus | 1 | 2007 | 6 | 0.070 |
Why?
| Retroperitoneal Neoplasms | 1 | 2007 | 20 | 0.070 |
Why?
| Fibroma | 1 | 2007 | 39 | 0.070 |
Why?
| Immunoenzyme Techniques | 1 | 2007 | 145 | 0.070 |
Why?
| Immunophenotyping | 1 | 2007 | 109 | 0.070 |
Why?
| Sarcoma | 1 | 2007 | 67 | 0.070 |
Why?
| Risk Factors | 1 | 2013 | 3629 | 0.060 |
Why?
| Pregnancy | 2 | 2024 | 2604 | 0.050 |
Why?
| Ovarian Neoplasms | 1 | 2007 | 447 | 0.050 |
Why?
| Public Health | 1 | 2024 | 203 | 0.050 |
Why?
| Lactobacillus | 1 | 2021 | 7 | 0.050 |
Why?
| Biological Specimen Banks | 1 | 2021 | 21 | 0.050 |
Why?
| Cytodiagnosis | 1 | 2021 | 42 | 0.050 |
Why?
| Vulnerable Populations | 1 | 2021 | 45 | 0.050 |
Why?
| Early Detection of Cancer | 1 | 2021 | 167 | 0.040 |
Why?
| Pandemics | 1 | 2021 | 562 | 0.030 |
Why?
| Vaccines, Subunit | 1 | 2016 | 15 | 0.030 |
Why?
| Chorioamnionitis | 1 | 2015 | 15 | 0.030 |
Why?
| Parity | 1 | 2015 | 50 | 0.030 |
Why?
| Mississippi | 1 | 2015 | 88 | 0.030 |
Why?
| Puerperal Disorders | 1 | 2015 | 28 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2016 | 115 | 0.030 |
Why?
| Pre-Eclampsia | 1 | 2015 | 54 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2016 | 225 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 231 | 0.030 |
Why?
| Host-Pathogen Interactions | 1 | 2016 | 135 | 0.030 |
Why?
| Proteome | 1 | 2016 | 173 | 0.030 |
Why?
| Vaccination | 1 | 2016 | 271 | 0.030 |
Why?
| United States | 1 | 2024 | 4874 | 0.030 |
Why?
| Proteomics | 1 | 2016 | 330 | 0.030 |
Why?
| Communication | 1 | 2015 | 246 | 0.030 |
Why?
| Cytokines | 1 | 2016 | 613 | 0.030 |
Why?
| Rural Health Services | 1 | 2015 | 164 | 0.030 |
Why?
| Research Design | 1 | 2015 | 342 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2015 | 579 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1378 | 0.030 |
Why?
| Body Mass Index | 1 | 2015 | 656 | 0.030 |
Why?
| Cell Line | 1 | 2012 | 1021 | 0.020 |
Why?
| Infant, Newborn | 1 | 2015 | 2766 | 0.020 |
Why?
| DNA, Recombinant | 1 | 2007 | 15 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2011 | 1416 | 0.020 |
Why?
| Clone Cells | 1 | 2007 | 78 | 0.020 |
Why?
| Treatment Outcome | 1 | 2015 | 5155 | 0.020 |
Why?
| Retrospective Studies | 1 | 2015 | 6134 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2007 | 1043 | 0.010 |
Why?
| Cells, Cultured | 1 | 2007 | 1581 | 0.010 |
Why?
| Adolescent | 1 | 2011 | 6390 | 0.010 |
Why?
| Male | 1 | 2007 | 25399 | 0.000 |
Why?
|
|
Greenfield's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|